Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Mar 1;143(3):215-220.
doi: 10.1001/jamaophthalmol.2024.6058.

Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide

Bradley J Katz  1 , Michael S Lee  2 , Norah S Lincoff  3 , Anne S Abel  2 , Somya Chowdhary  4 , Brian D Ellis  4 , Ahmad Najafi  5 , John Nguyen  4 , Meagan D Seay  1 , Judith E A Warner  1   6
Affiliations
Comment

Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide

Bradley J Katz et al. JAMA Ophthalmol. .

Abstract

Importance: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.

Objective: To report ophthalmic complications associated with the use of semaglutide or tirzepatide.

Design, setting, and participants: This was a retrospective case series. All patients were initially seen in a community setting. Patients experiencing an ophthalmic complication in association with the use of semaglutide or tirzepatide were included in this analysis.

Exposures: Patients described were using either semaglutide or tirzepatide.

Main outcomes and measures: Visual acuity and visual field defects.

Results: A total of 9 patients (mean [SD] age, 57.4 [11.6] years; age range, 37-77 years; 5 female [56%]; 4 male [44%]) were included in this study. Seven patients with nonarteritic ischemic anterior optic neuropathy, 1 patient with bilateral papillitis, and 1 patient with paracentral acute middle maculopathy were reported. Atypical features included sequential ischemic optic neuropathy, bilateral disc swelling at presentation, and progressive vision loss.

Conclusions and relevance: In this case series study, it was not possible to determine if there is a causal link between these drugs and the ophthalmic complications reported. In some cases, it is hypothesized that rapid correction of hyperglycemia induced by these drugs, rather than a toxic effect of the drugs, could be associated with the ophthalmic complications reported.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Katz reported having an equity interest in and is a consultant for Avulux. Dr Lee reported receiving consultant fees from Eli Lilly and Panbela, grants from Invex, advisory board fees from Viridian, and personal fees from Horizon outside the submitted work. Dr Najafi reported previously being affiliated with Spectrum Eye Care Inc, where the information for this study was gathered, but has since left that institution and is currently a cornea and external disease fellow at University of Minnesota. No other disclosures were reported.

Comment on

References

    1. Garvey WT, Frias JP, Jastreboff AM, et al. ; SURMOUNT-2 Investigators . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X - DOI - PubMed
    1. Tichy EM, Hoffman JM, Tadrous M, et al. . National trends in prescription drug expenditures and projections for 2024. Am J Health Syst Pharm. 2024;81(14):583-598. doi:10.1093/ajhp/zxae105 - DOI - PubMed
    1. McPhillips D. CNN Exclusive: prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients. Accessed September 19, 2024. https://www.cnn.com/2023/09/27/health/semaglutide-equitable-access/index...
    1. Vilsbøll T, Bain SC, Leiter LA, et al. . Semaglutide, reduction in glycated hemoglobin, and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897. doi:10.1111/dom.13172 - DOI - PMC - PubMed
    1. Wai KM, Mishra K, Koo E, et al. . Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study. Am J Ophthalmol. 2024;265:39-47. doi:10.1016/j.ajo.2024.04.010 - DOI - PubMed

MeSH terms